Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools
In Their Own Words
The following excerpt is from an op-ed that first appeared in The Hill on May 9th, 2024.
To appreciate one of the great snafus of American health care, consider the plight of people who are poor, elderly — often with a disability — and insured by both Medicare and Medicaid.
One might think having two insurers must be better than one. But these two programs were never meant to work together. Rather than cooperating, the programs follow rules that create incentives for each partner to shift costs to the other, while patients are stuck in the middle, without the care they need.
For dually eligible Americans, bureaucratic nightmares are their daily realities.
These accounts are emblematic of the problems that plague the nearly 13 million dually eligible individuals with disabilities or are old enough to qualify for Medicare and poor enough to get Medicaid. Nearly all make less than $20,000 a year. They are arguably sicker than any other group enrolled in Medicare or Medicaid, with lifespans that are a decade shorter than other patients. And they cost the government a cool half a trillion dollars a year — a sum greater than any other group and one that will surely rise as the country ages.
Read the entire op-ed here.

Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools
A 2024 Study Showing How Even Small Copays Reduce PrEP Use Fueled Media, Legal, and Advocacy Efforts As Courts Weighed a Case Threatening No-Cost Preventive Care for Millions
Chart of the Day: LDI Researchers Report Major Coverage Differences Across ACA and Medicaid Plans, Affecting Access to Drugs That Treat Chemo-Related Nausea
Insurers Avoid Counties With Small Populations and Poor Health but a New LDI Study Finds Limited Evidence of Anticompetitive Behavior
A Proven, Low-Risk Treatment Is Backed by Major Studies and Patient Demand, Yet Medicare and Insurers Still Make It Hard To Use
Chart of the Day: Medicare-Medicaid Plans—Created to Streamline Care for Dually Eligible Individuals—Failed to Increase Medicaid Participation in High-Poverty Communities